Crescent Biopharma (CBIO) Current Assets (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Current Assets of $179.0 million for Q2 2026, up 16.07% year-over-year from $154.2 million in Q2 2025, and down 8.47% quarter-over-quarter from $195.6 million in Q1 2026.
Crescent Biopharma (CBIO) Current Assets (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Current Assets for 14 consecutive years, with $179.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets rose 16.07% year-over-year to $179.0 million; the TTM figure through Jun 2026 stood at $179.0 million (up 16.07% YoY), while the FY2025 annual figure was $236.7 million, up 579.96% from the prior year.
- Current Assets eased to $179.0 million in Q2 2026 per CBIO's latest filing, from $195.6 million in the prior quarter.
- Across five years, Current Assets topped out at $236.7 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
- Historically, Current Assets has averaged $82.3 million across 5 years, with a median of $57.1 million in 2022.
- Annual changes were most pronounced in 2025 — Current Assets plunged 81.99% — and 2026, when it surged 3163.64%.
- Crescent Biopharma's Current Assets stood at $50.7 million in 2022, then slipped by 13.65% to $43.8 million in 2023, then fell by 20.52% to $34.8 million in 2024, then jumped by 579.96% to $236.7 million in 2025, then fell by 24.36% to $179.0 million in 2026.
- Business Quant data shows CBIO's Current Assets at $179.0 million in Q2 2026, $195.6 million in Q1 2026, and $236.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 179.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.01 Mn |
| Mar 31, 2026 | 195.56 Mn |
| Dec 31, 2025 | 236.66 Mn |
| Sep 30, 2025 | 134.56 Mn |
| Jun 30, 2025 | 154.23 Mn |
| Mar 31, 2025 | 5.99 Mn |
| Dec 31, 2024 | 34.80 Mn |
| Sep 30, 2024 | 15.65 Mn |
| Jun 30, 2024 | 23.86 Mn |
| Mar 31, 2024 | 33.27 Mn |
| Dec 31, 2023 | 43.79 Mn |
| Sep 30, 2023 | 52.01 Mn |
| Jun 30, 2023 | 60.37 Mn |
| Mar 31, 2023 | 68.09 Mn |
| Dec 31, 2022 | 50.71 Mn |
| Sep 30, 2022 | 53.85 Mn |
| Jun 30, 2022 | 61.26 Mn |
| Mar 31, 2022 | 77.46 Mn |
| Dec 31, 2021 | 90.79 Mn |
| Sep 30, 2021 | 104.13 Mn |